Lupin Pharmaceuticals, Inc. committed to quality, innovation

August 10, 2014

Lupin Pharmaceuticals, Inc. (“Lupin”), ranked last year as the fifth largest generic company in the U.S., focuses on delivering high-quality, branded and generic pharmaceutical products to the marketplace. Its growth rate of 9.9% year over year, in terms of number of prescriptions, makes Lupin the fastest growing generic supplier among the top five manufacturers.*

 

Lupin Pharmaceuticals, Inc. (“Lupin”), ranked last year as the fifth largest generic company in the U.S., focuses on delivering high-quality, branded and generic pharmaceutical products to the marketplace. Its growth rate of 9.9% year over year, in terms of number of prescriptions, makes Lupin the fastest growing generic supplier among the top five manufacturers.*

In 2003, Lupin opened its doors in Baltimore, Maryland with three employees and received its first U.S. generic product approval. Today, Lupin, the exclusive U.S. distributor for all products developed and manufactured by its parent company, Lupin Ltd. and other affiliates, has more than 70 products, generating more than $800 million in net revenues.

Lupin’s sustained growth year over year can be attributed to its valuable pipeline, solid customer relationships, and commitment to quality. Lupin has 94 ANDAs pending FDA approval as of May 2014, and has introduced 19 generic products last fiscal year. Lupin’s products are generally vertically integrated, which ensures quality control throughout each step of product development and manufacturing. Lupin has an unparalled advantage over its competitors because of its control of its supply chain and the ability to offer competitive pricing.

“Over the last decade, Lupin has successfully ring-fenced its business by creating competitive advantages, which have become distinctive differentiators,” according to Dr. Kamal K. Sharma, Lupin Ltd.’s managing director. “We have done that by calibrating our choice of markets; entry into new geographies, new therapies, the business and product mix; and a rigorous attention to input costs in a never-ending quest for better efficiencies.”

R&D

Research and development (R&D) is top of mind for Lupin, which has invested more than 8% of its FY 2013 net sales in this area. In FY 2014, its U.S. generics business grew by 32%, reaching revenues of $723 million, up from $548 million in the previous fiscal year. Key launches included Duloxetine HCl DR Capsules, Abacavir Lamivudine Zidovudine Tablets, Gatifloxacin Ophthalmic Solution, and Niacin ER Tablets. Lupin plans to expand its portfolio with product offerings in new therapeutic areas, including dermatology and respiratory diseases.

Lupin’s affiliate company, Lupin Inc., has announced plans to develop a new 30,000 square-foot, state-of-the-art R&D facility in Coral Springs, Fla. At this R&D site, Lupin Inc. will produce both branded and generic oral and nasal inhalation products. Lupin remains committed to investing in the development of new branded and generic products in various therapeutic areas and in multiple dosage forms.

Quality and Supply Chain

Lupin has earned its reputation for reliability by consistently delivering high-quality products. It has a strong corporate culture of excellence to ensure strict adherence to FDA regulations. Its global affiliates also have a commitment to quality, and continue to expand their manufacturing capacity with the addition of state-of-the-art facilities. This enables Lupin to strengthen its overall supply chain by creating efficiencies that ensure cutting edge response time and continuous product supply. Lupin continues to meet and exceed customers’ expectations.

For more information, please visit www.lupinpharmaceuticals.com.

*IMS Health, National Prescription Audit, September 2013